marked.bio

Company

Ascentage Pharma Group

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

APG-2449 2osimertinib 1

Trials

3 of 3 trials shown

  1. APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

    Recruiting Phase 1 Ascentage Pharma Group Started 2024Primary completion 2027-05 NCT06687070

    APG-2449pegylated liposomal doxorubicin

    Patients with histologically and/or cytologically confirmed ALK/ROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.

    ALK fusionROS1 fusionPlatinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor

  2. A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

    Active, not recruiting Phase 1 Ascentage Pharma Group Started 2019Primary completion 2025-12 NCT04001777

    APG-1252osimertinib FDA EU

    Cohort 3: Patients with advanced EGFR-mutated NSCLC not previously treated with TKI.

    EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer

  3. APG-2449 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Ascentage Pharma Group Started 2019Primary completion 2027-12 NCT03917043

    APG-2449

    …stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, e…

    ALK fusionROS1 fusionAdvanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer